Delivery Order SPE2DB22D2005-SPE2DB26FJEH0
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,155.66 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 27, 2025, with completion scheduled for August 28, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $2,455.79 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on August 1, 2025, with an ultimate completion date of August 4, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes treatment and represents part of the agency's ongoing...
- The Defense Logistics Agency awarded a $2,145.94 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of NovoLog 100 Unit/ML vials (10 ML units). This is a firm fixed-price, non-set-aside contract with a completion date of August 11, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes management and represents a critical pharmaceutical commodity within the...
- The Defense Logistics Agency awarded a delivery order valued at $2,020.06 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10 mL) on July 14, 2025, with completion expected by July 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the contractor's Conshohocken, Pennsylvania facility. NovoLog is a rapid-acting insulin analog used in diabetes management, representing the type of critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order valued at $1,296.60 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on September 4, 2025, with an ultimate completion date of September 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product commonly used in military and federal healthcare...
- The Defense Logistics Agency awarded a $9,344.14 delivery order to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) with an ultimate completion date of August 13, 2025. This firm fixed-price contract was competitively awarded with no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management, representing part of the broader pharmaceutical supply chain...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL) with a contract value of $1,248.90. This is a firm fixed-price delivery order with no set-aside designation, reflecting competitive procurement practices. The order is set to be completed by September 11, 2025, and will be fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting...
- The Defense Logistics Agency awarded a $1,296.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a non-set-aside contract with an ultimate completion date of April 24, 2025, and represents a child delivery order under a larger contract vehicle. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin used in diabetes management,...
- The Defense Logistics Agency awarded a delivery order valued at $1,248.90 to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of NovoLog 100 Unit/mL vials (10 mL). This is a firm fixed price delivery order with no set-aside designation, utilizing competitive procurement procedures. The order is scheduled for completion by July 21, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product...
- The Defense Logistics Agency awarded a delivery order valued at $4,654.66 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/mL vials (10mL) on June 20, 2025, with an ultimate completion date of June 23, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which carries a total value of $999,999,999.00 and extends through December 2026. The...
- SPE2DB22D2005Indefinite Delivery Contract
- SPE2DB22D2005-SPE2DB26FJEH0Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $2,003.37 to AmerisourceBergen Drug Corp for NovoLog 100 Unit/ML vials (10 mL) on October 22, 2025, with completion scheduled for October 23, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. NovoLog is a rapid-acting insulin product used in diabetes management, reflecting the Defense Logistics Agency's ongoing procurement of critical pharmaceutical supplies for military and federal healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026. The parent IDC enables the contractor to supply a broad range of pharmaceutical products, vaccines, and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal vendor with an extensive portfolio of medical procurement contracts, demonstrating capability to fulfill federal medical supply needs across multiple therapeutic domains through open competition.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 10/22/25 |